# Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers

> **NCT03118817** · PHASE1 · COMPLETED · sponsor: **Hanmi Pharmaceutical Company Limited** · enrollment: 65 (actual)

## Conditions studied

- Solid Tumor

## Interventions

- **DRUG:** HM95573

## Key facts

- **NCT ID:** NCT03118817
- **Lead sponsor:** Hanmi Pharmaceutical Company Limited
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-05-19
- **Primary completion:** 2020-02-04
- **Final completion:** 2020-02-04
- **Target enrollment:** 65 (ACTUAL)
- **Last updated:** 2020-08-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03118817

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03118817, "Expansion Study to Evaluate the Efficacy and Safety of HM95573 in BRAF, KRAS or NRAS Mutant Solid Cancers". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03118817. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*